CHRNA7 and hepatocellular carcinoma: Thus, it is necessary to identify CSCs markers like the α7-nAChR in the context of the present study for screening and early identification of patients with HCC, who are at high risk of disease relapse and likely to benefit from postoperative adjuvant therapy.